Pfizer/BioNTech COVID-19 booster 95.6% effective against disease: study A 30-microgram booster dose showed a relative vaccine efficacy of 95.6% in individuals who had previously received the Pfizer/BioNTech primary two-dose series, the companies announced. https://ift.tt/2XyB5vf https://ift.tt/3Ca9uzO Markets October 21, 2021 at 07:16PM
Post a Comment